An active component in the medicine is Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. The component binds to the intracellular catalytic domain of epidermal growth factor receptor tyrosine kinase to inhibit the EGFR phosphorylation. It blocks the signal transduction events and tumorigenic effects associated with EGFR activation. An antineoplastic agent that functions as a Protein kinase inhibitor for EGFR-associated tyrosine kinase. It can be used in the treatment of Non-small cell lung cancer.
Given popular brand medicine Tarceva is intended to treat lung and pancreatic cancer. It slows or stops the growth of cancer cells.
The working of this medicine depends on the action mechanism of the active component. Erlotinib Hydrochloride targets the epidermal growth factor receptor tyrosine kinase, which is expressed and mutated in various forms of cancer. The component binds in a reversible way to the adenosine triphosphate binding site of the receptor. This way Tarceva stops the further growth of the cancer cells in the body.
The mentioned medicine is available in dosages as follows:
- 100 mg: It should be taken on an empty stomach at least 1 hour before or 2 hours after a meal, as directed by the doctor
- 150 mg: The tablet should be administered on an empty stomach as directed by the doctor, usually once a day
Do not eat grapefruit or drink grapefruit juice while consuming this medication. Grapefruit can increase the chance of side effects with this medicine.